Mylan New Launches On Track For $1bn In 2019, But It's Not Enough
Executive Summary
New complex generic and biosimilar launches like Wixela, Fulphila and generic Copaxone generated $250m in the first quarter, but the company's sales and earnings declined, pointing to big challenges in the base generics business.